There have been a number of significant advances in biological therapies for malignant disease, and several have gone to the clinical trial stage. Here we combine two well-developed biotherapies to maximize delivery, efficacy and safety and evaluate this new combination therapy using molecular imaging. Using an immune cell therapy based on cytokine induced killer (CIK) cells, we have demonstrated efficacy in clinical trials, and revealed, in preclinical trials, that these cells traffic to tumor sites and destroy cells from a variety of cancer types. The tempo of CIK cell trafficking to the tumor in these models suggested that in addition to their tumoricidal activity, they might be useful as a delivery vehicle for oncolytic viruses to enhance virotherapy. Here we propose a combination biotherapy, where the tumoricidal CIK cells are used to deliver replication competent, but modified, oncolytic vaccinia viruses to tumor targets. The modifications in the viruses have disabled them such that they are only capable of an effective infection cycle in tumor cells. Several of these vaccinia strains will be entering clinical trials within the next 3-9 months. Since immunotherapy is limited by the need for repeated cell infusions to achieve sufficient tumor cell killing, and the greatest problem for virotherapy is achieving successful systemic delivery of the virus to the tumor, the combination therapy is complementary and addresses the limitations of each individual therapy. We hypothesize that the infection of CIK cells with vaccinia virus immediately prior to their use in a tumor-bearing host will enable the CIK cells to act as a carrier vehicle, delivering an amplified payload of virus directly to the tumor. Preliminary results indicate that vaccinia undergoes an uncharacteristic replication cycle in CIK cells, releasing virus at the time these cells reach their tumor target, and that this tempo of replication can be utilized to deliver virotherapy to tumors in living subjects. The objective of this project therefore is to use advanced imaging approaches to refine this combination therapy in preclinical models and use this data to design and implement a Phase I clinical trial. This will be accomplished through three specific aims. First, we will characterize vaccinia-CIK cell interactions in culture to optimize the timing of infection of the effector cells and delivery of combined therapies. Second we will characterize immune cell trafficking patterns and viral infection in murine cancer models using imaging. Lastly, we will test the optimized conditions for this dual biotherapy in a limited clinical trial using PET imaging as an outcome measure. Imaging can greatly enhance the development of novel therapies and here we will optimize a novel combination of biotherapies using advanced molecular imaging.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA114747-05
Application #
7879479
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
5
Fiscal Year
2009
Total Cost
$222,655
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Natarajan, Arutselvan; Patel, Chirag B; Habte, Frezghi et al. (2018) Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression. Sci Rep 8:633
Habte, Frezghi; Natarajan, Arutselvan; Paik, David S et al. (2018) Quantification of Cerenkov Luminescence Imaging (CLI) Comparable With 3-D PET Standard Measurements. Mol Imaging 17:1536012118788637
Natarajan, Arutselvan; Patel, Chirag B; Ramakrishnan, Sindhuja et al. (2018) A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1 : Validation in Mouse Models and Human Cancer Tissues. Clin Cancer Res :
Sun, Yao; Zeng, Xiaodong; Xiao, Yuling et al. (2018) Novel dual-function near-infrared II fluorescence and PET probe for tumor delineation and image-guided surgery. Chem Sci 9:2092-2097
Hong, Su Hyun; Sun, Yao; Tang, Chu et al. (2017) Chelator-Free and Biocompatible Melanin Nanoplatform with Facile-Loading Gadolinium and Copper-64 for Bioimaging. Bioconjug Chem 28:1925-1930
Shen, Bin; Behera, Deepak; James, Michelle L et al. (2017) Visualizing Nerve Injury in a Neuropathic Pain Model with [18F]FTC-146 PET/MRI. Theranostics 7:2794-2805
Loft, Mathias Dyrberg; Sun, Yao; Liu, Changhao et al. (2017) Improved positron emission tomography imaging of glioblastoma cancer using novel 68Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR). Amino Acids 49:1089-1100
Natarajan, Arutselvan; Mayer, Aaron T; Reeves, Robert E et al. (2017) Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Mol Imaging Biol 19:903-914
Hori, Sharon Seiko; Lutz, Amelie M; Paulmurugan, Ramasamy et al. (2017) A Model-Based Personalized Cancer Screening Strategy for Detecting Early-Stage Tumors Using Blood-Borne Biomarkers. Cancer Res 77:2570-2584
Ronald, John A; Kim, Byung-Su; Gowrishankar, Gayatri et al. (2017) A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant. Cancer Res 77:2893-2902

Showing the most recent 10 out of 424 publications